Celenge has announced positive results of its phase 2 clinical trial treating systematic lupus erythematosus (SLE), more commonly referred to as lupus. The drug, C-220, an oral immune-modulatory compound showed greater disease state improvement when compared with placebo results. The trial was aimed at testing safety, tolerability, and pharmacokinetics with efficacy endpoints being changes in cutaneous lupus area and severity activity index. Celenge will join few biotech companies in the lupus market after GlaxoSmithKline became the first company in half a century to gain FDA approval for treatment. Read the full press release here.
